Introduction
The efficient use of apheresis machines for PBSC harvesting will achieve cost savings and by reducing the waiting time for this procedure, will avoid delay in patients progressing to high-dose chemo-radiotherapy with autologous stem cell transplantation. There is increasing pressure on this resource as a result of the wider applications of apheresis such as therapeutic plasma exchange, red cell exchange, platelet apheresis from healthy donors, granulocyte or buffy coat collections and stem cell harvests from donors for allogeneic transplantation. PBSC collection as a source of stem cells is now preferred to bone marrow as it has been shown to provide more rapid engraftment and reduced toxicity. 1, 2 The number of patients scheduled for PBSC harvesting is increasingly expanding in line with the role of high-dose chemotherapy and autologous stem cell rescue. Autologous transplantation is now considered the treatment of choice for initial therapy of multiple myeloma and for relapsed high-grade non-Hodgkin's and Hodgkin's lymphoma, in addition to experimental procedures in non-malignant disorders such as autoimmune disease. 3 Intravenous cyclophosphamide supported by haematopoietic growth factors for example, G-CSF, is a commonly used priming regimen for patients with myeloma and lymphoma. Although high doses of cyclophosphamide (4-7 g/m 2 ) are effective, 4, 5 lower doses (1.2-2 g/m 2 ) are as effective but with less toxicity. 4, [6] [7] [8] [9] The optimal monitoring and timing of PBSC harvesting following low-dose cyclophosphamide does however remain to be determined. A better insight into the kinetics may improve the logistical organization of providing a PBSC-harvesting service. In this study, we examined patients primed with cyclophosphamide/G-CSF with respect to their mobilization kinetics and the relationship between timing and success of PBSC harvesting. This was achieved through analysis of PB WBC counts, PB CD34 þ counts and subsequent stem cell harvest yields. We found that a PB CD34 þ count X10/ml was predictive of an adequate harvest but there was no benefit to checking the PB CD34 þ count or booking apheresis before day 9 post-cyclophosphamide.
Patients and methods

Patients
Patients with haematological malignancy undergoing PBSC mobilization between January 2003 and December 2004 in the Yorkshire Blood and Marrow Transplantation Programme were analysed. Those receiving cyclophosphamide/ G-CSF as a first attempted mobilizing regimen were selected. All patients were primed as part of a planned protocol for high dose chemotherapy.
Stem cell mobilization and harvesting
Two hundred and six patients were primed for PBSC collection of which 168 (81.6%). received cyclophosphamide/G-CSF to mobilize PBSC. Data were collected on those 168 patients to analyse mobilization kinetics including the time from chemotherapy administration until apheresis, PB CD34 þ cell counts, PB WBC counts and stem cell harvest yields. Patients received priming chemotherapy with 1.5-3 g/m 2 cyclophosphamide intravenously with hydration and MESNA for uro-epithelial protection on day 0 (Table 1) . Subcutaneous G-CSF 5-10 mg/kg was administered the day after cyclophosphamide for 161 patients and continued daily until completion of apheresis. For seven patients, G-CSF 5 mg/kg was commenced 4 days after the cyclophosphamide prime and PB CD34 þ count first checked a further 5 days after this. Apheresis was conducted by the Yorkshire Blood and Marrow Transplantation Programme Managed Apheresis Network, which incorporates five apheresis machines on three sites. Initial target processing is either 2-3 times estimated patient blood volume or a fixed target of 12 l. Venous blood samples were collected in EDTA and the PB CD34 þ count was analysed using two colour flow cytometry according to the International Society of Haematotherapy and Graft Engineering gating strategy. 10 The time that apheresis was scheduled to begin varied between 6-10 days after chemotherapy priming, depending on local hospital policy. The PB CD34 þ count was therefore first checked 6 and 10 days after priming and apheresis generally commenced when the CD34 þ cell count was X10/ml.
Harvesting definitions
To ensure adequate engraftment after autologous transplantation, a minimum harvest yield of 2.0 Â 10 6 CD34 þ cells per kg is required. 11 An adequate/successful harvest was therefore defined as one in which the total yield (sum of all leukapheresis procedures) was X2. þ cell count, WBC count and leukapheresis yield was assessed by Pearson rank correlation. Factors that might influence harvesting success were analysed in univariate analysis by odds ratios then combined in a multivariate regression model. The effect of differences in the priming cyclophosphamide and G-CSF doses on harvesting failure rate was tested by Fisher's exact test and on total harvest yield by Kruskal-Wallis. Harvesting outcome was compared between patients grouped by the day they first attended for blood counts. Total harvest yield, failure rates and the number of days attending were compared by Kruskal-Wallis for all groups simultaneously. Where there was a significant difference, individual days were compared by Mann-Whitney using the 'exact' method and the Bonferroni correction to account for multiple testing. Table 1 . The male/ female ratio was 1.67:1 and the median age was 55.5 years (range 19-70). A total of 130/168 (77%) patients mobilized adequate numbers of PBSC. Two hundred and four leukapheresis procedures were performed in total with a median PBSC collection per procedure of 2.18 Â 10 6 /kg (range 0.1-14.5). Median time from prime to first leukapheresis was 9 days (range 7-15). For those patients who mobilized adequate numbers of PBSC, 60% required only one leukapheresis, 34% required two and 6% required three. Of the 38 patients who failed to mobilize, nine harvested o2 Â 10 6 /kg (of whom one had an infective complication) and 29 did not undergo leukapheresis (inadequate PB CD34 þ counts in 27, infective complications in two). For the 139 patients for whom mobilization was therefore attempted, the median total harvest yield was 3.9 Â 10 6 /kg (range 0.2-14.5). The number of failed mobilizations by disease was: multiple myeloma 10/88 (11%), diffuse large B-cell lymphoma 9/25 (36%), follicular In univariate analysis, patients with myeloma were significantly more likely to harvest successfully than those with other haematological malignancies (Po0.001, odds ratio ¼ 4.2). The chance of successful harvesting increased if patients had fewer lines of prior therapy (Po0.001, odds ratio ¼ 0.31); successful harvest after one line 76/82 (93%), two lines 43/65 (66%), three lines 9/16 (56%), four or more 1/3 (33%). Prior exposure to alkylating agents or platinumbased chemotherapy did not have a significant impact. In multivariate analysis, only the number of prior lines of therapy remained significant (P ¼ 0.003).
Results
Patient characteristics are illustrated in
PB CD34
þ cell count but not WBC count predicts for success of PBSC mobilization and harvesting A significant correlation was found between the PB CD34 þ cell count and same day leukapheresis yield (r ¼ 0.8448, Po0.0001; Figure 1 ), as reported previously. For those leukapheresis procedures undertaken when the PB CD34 þ cell count was X10/ml (n ¼ 180) there was a 61% chance of a same day harvest yield of X2 Â 10 6 /kg, falling to 22% for the higher target of X5 Â 10 6 /kg. Equally, those harvested when PB CD34 þ cell count was o10/ml (n ¼ 24) had a 0% chance of harvesting X2 Â 10 6 /kg ( Table 2 ). The WBC count did not correlate with the same day leukapheresis yield (r ¼ 0.0117, P ¼ 0.8682) in patients harvested on the basis of favourable PB CD34 þ cell counts. If however, the WBC count is o1 Â 10 9 /l, less than 6% of patients had PB CD34 þ counts X10 but if the WBC count is 45 Â 10 9 /l, this rises to over 60% (Figure 2 ).
Assessment of mobilization kinetics demonstrates the optimum timing for PBSC harvesting following priming with cyclophosphamide and G-CSF On a given day after intravenous cyclophosphamide, the percentage of patients attending who were actually harvested, the number achieving a yield X2 Â 10 6 /kg in one collection and the median apheresis yield for that day was analysed (Figure 3) . No patient was ready for apheresis by day 6. On day 7, o10% of those attending for PB CD34 þ cell counts were harvested, only 3% achieved a harvest X2 Â 10 6 /kg in one leukapheresis and the median yield was 1.5 Â 10 6 /kg. On day 8, 41% were harvested, 30% were X2 Â 10 6 /kg with a median yield of 3.1 Â 10 6 /kg. Day 9, 68% were harvested, 50% were X2 Â 10 6 /kg with a median harvest of 3.3 Â 10 6 /kg 60 and 58% were harvested on days 10 and 11, respectively while 24 and 11% were X2 Â 10 6 /kg with a median harvest yield of 1.5 and 1.2 Â 10 6 /kg, respectively.
Patients were then grouped by the first day that they attended for blood counts (days 6-10) and these groups compared to determine differences in outcome ( Figure 4 ). There was a significant difference between groups for the number of days that patients attended the unit (Kruskal-Wallis: Po0.0001). Patients first attending day 9 had to attend on significantly fewer occasions þ cell count and the same day leukapheresis yield (n ¼ 204). The correlation value r ¼ 0.8448 and this was highly significant (Po0.0001). The correlation remains highly significant after logarithmic transformation (r ¼ 0.8725, Po0.0001).
Table 2
Effectiveness of PB CD34 + counts in predicting the same day harvest yield þ cell count is unlikely to be X10/ml until the WBC count is X1 Â 10 9 /l following cyclophosphamide/G-CSF priming (n ¼ 442). When the WBC was o1, the PB CD34 þ count was X10/ml in 5/85 (5.9%). When the WBC was 1-4, PB CD34 þ counts were X10/ml in 70/159 (44%), when 5-9, 42/68 (62%), when 10-19, 46/73 (63%) and when 419, 39/57 (68%). to achieve a successful harvest compared with those first attending days 6-8 (Mann-Whitney: day 6, P ¼ 0.0004; day 7, P ¼ 0.0004; day 8, P ¼ 0.037; day 10, P ¼ 0.223). Days 9 and 10 attendees had lower failure rates than those first attending days 6-8 but there was no significant overall difference between groups (KruskalWallis: P ¼ 0.0539). For successful harvests, days 9 and 10 attendees total harvest yield was highest but again there was no significant difference between groups (KruskalWallis: P ¼ 0.0696).
Discussion
The correlation between PB CD34 þ count and harvest yield (r ¼ 0.8448) is in keeping with previous studies which reported r-values of 0.84-0.95. [11] [12] [13] [14] [15] [16] Recommendations for the level of PB CD34 þ cell count that should be used to initiate apheresis has varied from 8 to 20/ml. [16] [17] [18] [19] If harvesting is initiated at a lower PB CD34 þ count, daily yield will be lower and more apheresis days are required to achieve an adequate harvest. If too high a target is set, fewer patients will reach the target count thereby increasing the failure rate. In our series, a threshold PB CD34 þ count of 10/ml resulted in a same day yield X2.0 Â 10 6 /kg in 61% of cases while 100% of those with a PB count o10/ml failed to achieve a yield X2.0 Â 10 6 /kg showing this threshold to be discriminatory. The lack of correlation between WBC count and harvest yield (r ¼ 0.0117) is supported by previous studies, in which r-values ranged from À0.065 to 0.43. [12] [13] [14] 16, 17 WBC count is therefore less reliable than PB CD34 þ count for initiating apheresis. If the WBC count is low, the PB CD34 þ count is also likely to be low 14, 16, 19 leading some to suggest that monitoring CD34 þ counts should begin when the WBC count exceeds 1-5 Â 10 9 /l. 14, 16 Analysing the utility of WBC in predicting yield is problematic when another variable, that is PB CD34 þ count is being used to select patients for harvesting. Our data show that until WBC count recovers to 41 Â 10 9 /l, the PB CD34 þ count is unlikely to be greater than 10/ml and this may inform units where a PB CD34 þ count is not immediately available.
Haematological diagnosis, amount of prior chemotherapy, prior exposure to alkylating agents and platinum-based therapy have been implicated as risk factors for failing stem cell collection, but the relative importance of each has been a matter for debate. [20] [21] [22] In our series, only an increased number of lines of previous therapy was a significant risk factor for harvesting failure.
Identifying the optimal time to book a harvest requires an understanding of the pharmacokinetics of PBSCs following low-moderate dose cyclophosphamide/G-CSF. This will reduce inconvenience for the patient by reducing unnecessary attendances and the number of failed harvests. It will reduce costs incurred on patient transport, blood tests, leukapheresis runs and staffing. Finally, it reduces the days when apheresis machines are reserved for harvesting but inactive because patient's PB CD34 þ counts have not reached an adequate level.
A median time to first harvest of 12-18 days has been reported for various chemotherapy regimens combined with G-CSF. [23] [24] [25] [26] During the time period of our study, 28 patients (unpublished data) received disease-specific chemotherapy primes with G-CSF and the median time to first harvest was 13 days (range [11] [12] [13] [14] [15] [16] [17] [18] . Stem cell recovery is more rapid however following low-dose cyclophosphamide/G-CSF. At doses of 1.5 g/m 2 , in patients with myeloma and lymphoma, median time to first harvest or peak PB CD34 þ count has been 8-10 days. 6-8 Jantunen et al. 4 found that the peak PB CD34 þ count was significantly earlier in patients with myeloma primed with cyclophosphamide/G-CSF 1. prime lymphoma patients, median time to first harvest was 15 and 10 days respectively. 27 A limitation of this study was that the median total harvest yields were modest. Achieving a higher total harvest yield is desirable because although X2.0 Â 10 6
CD34
þ /kg is acceptable, doses X5 Â 10 6 CD34 þ /kg have been associated with improved outcome for allogeneic transplants and many consider this to be an optimal dose. 19 Interest in second autografts for patients with myeloma also provides an incentive to maximize harvest yield so that cells may be stored for a second procedure if needed. Setting a higher target will increase the total yield but also the number of procedures required. Although no statistically significant advantage was identified for first attendance day 9 compared with day 10, the median day 9 harvest yield was double that of day 10. It is therefore more likely that higher total harvest yields could be achieved if first attendance is on day 9. Another strategy to improve the yield may be to select ESHAP/G-CSF priming for lymphoma patients, for whom this appears to be superior. 27, 28 The optimal dose of G-CSF in combination with cyclophosphamide is unknown. In our study, no difference in outcome was found between the different priming regimens, but since only 11% did not receive 5 mg/kg G-CSF and only 17% did not receive 2 g/m 2 cyclophosphamide, this study has limited value in excluding a significant difference. In healthy donors primed with G-CSF alone, there appears to be a dose-response relationship between 5 and 10 mg/kg 29 and a higher yield has been reported in those receiving 16 vs 10 mg/kg 30 and 20 vs 10 mg/kg. 29 It is therefore possible that a higher dose of G-CSF could improve harvest yield. The peak of CD34 þ mobilization is approximately 3-6 h after G-CSF 31 and ensuring apheresis is timed to coincide with this may also improve yield.
Our study has uniquely showed the health care impact of planning harvesting for different times following a cyclophosphamide prime. By studying the pharmacokinetics of stem cell recovery we identified the optimal time to plan a harvest. We found no benefit in monitoring PB CD34 þ counts before day 9 since this neither reduced the harvest failure rate nor increased the total harvest yield. The failure rate may have been higher for those first attending days 6-8 because by the time they were ready to harvest, they had overrun their allocated time. Consequently, harvesting may not have been available over a weekend or the machines were fully occupied with new patients the following week. Time constraints may also have made it more likely that the minimum total harvest yield was accepted for these patients.
In conclusion, the optimal time to plan PBSC harvesting in patients with haematological malignancy after priming with low-moderate dose cyclophosphamide (1.5-3 g/m 2 ) on day 0 followed by G-CSF 5-10 mg/kg per day on day 1, is day 9. PB CD34 þ counts should then be monitored daily and harvesting commenced when they are X10/ml. The use of mobilization kinetics to plan and run an efficient harvesting service is important to ensure that a quality driven and delivered service can adapt to changing demands from clinicians responding to increased workload and diversity.
